Characterizing Fast and Slow Progressors in Anterior Circulation Large Vessel Occlusion Strokes
Overview
Authors
Affiliations
Background And Purpose: Infarct growth rate (IGR) in acute ischemic stroke is highly variable. We sought to evaluate impact of symptom-reperfusion time on outcomes in patients undergoing mechanical thrombectomy (MT).
Methods: A prospectively maintained database from January,2012-August,2020 was reviewed. All patients with isolated MCA-M1 occlusion who achieved complete reperfusion(mTICI2C-3), had a witnessed symptom onset and follow-up MRI were included. IGR was calculated as final infarct volume (FIV)(ml)/symptom onset to reperfusion time(hours) and was dichotomized according to the median value into slow-(SP) versus fast-progressors (FP). The primary analysis aimed to evaluate the impact of symptom-reperfusion time on 90-day mRS in SP and FP. Secondary analysis was performed to identify predictors of IGR.
Results: A total of 137 patients were eligible for analysis. Mean age was 63 ± 15.4 years and median IGR was 5.13ml/hour. SP(n = 69) had higher median ASPECTS, lower median rCBF<30% lesion volume, higher proportion of favorable collaterals and hypoperfusion intensity ratio (HIR)<0.4, higher minimal mean arterial blood pressure before reperfusion, and lower rates of general anesthesia compared to FP(n = 68). Symptom-reperfusion time was comparable between both groups. SP had higher rates of 90-day mRS0-2(71.9%vs.38.9%,aOR;7.226,95%CI[2.431-21.482],p < 0.001) and lower median FIV. Symptom-reperfusion time was associated with 90-day mRS0-2 in FP (aOR;0.541,95%CI[0.309-0.946],p = 0.03) but not in SP (aOR;0.874,95%CI[0.742-1.056],p = 0.16). On multivariable analysis, high ASPECTS and favorable collaterals in the NCCT/CTA model, and low rCBF<30% and HIR<0.4 in the CTP model were independent predictors of SP.
Conclusions: The impact of symptom-reperfusion time on outcomes significantly varies across slow-versus fast-progressors. ASPECTS, collateral score, rCBF<30%, and HIR define stroke progression profile.
Valente M, Bivard A, Yan B, Davis S, Campbell B, Mitchell P Front Neurol. 2024; 15:1476796.
PMID: 39372700 PMC: 11449691. DOI: 10.3389/fneur.2024.1476796.
Wouters A, Seners P, Yuen N, Mlynash M, Heit J, Kemp S Neurology. 2024; 103(6):e209814.
PMID: 39173104 PMC: 11343586. DOI: 10.1212/WNL.0000000000209814.
Verhey L, Lyons L, Sewell A, Grandfield R, Khan M, Mazaris P Interv Neuroradiol. 2024; :15910199241272715.
PMID: 39165187 PMC: 11571483. DOI: 10.1177/15910199241272715.
Sablic S, Dolic K, Budimir Mrsic D, cicmir-Vestic M, Matana A, Lovric Kojundzic S Neurol Int. 2024; 16(3):620-630.
PMID: 38921950 PMC: 11206870. DOI: 10.3390/neurolint16030046.
Miller M, Wideman B, Khan M, Henninger N AJNR Am J Neuroradiol. 2024; 45(7):879-886.
PMID: 38816020 PMC: 11286035. DOI: 10.3174/ajnr.A8234.